Nexstim Plc (NXTMH) - Financial and Strategic SWOT Analysis Review

November 2021 | 73 pages | ID: N8310406DBFEN
GlobalData

Abstracts

Nexstim Plc (NXTMH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nexstim Plc (Nexstim), a medical technology company that develops, manufactures and commercializes non-invasive brain stimulation technologies and devices to treat patients suffering from depressive disorders and chronic pain. The company provides Navigated Brain Therapy (NBT) system for the treatment of major depression disorder (MDD) and chronic neuropathic pain and Navigated Brain Stimulation (NBS) system for pre-surgical diagnostics. It develops products based on its proprietary SmartFocus TMS technology. Nexstim offers its products primarily to leading hospitals and universities through direct sales and distributors in the US, Europe, and Asia. The company has operations in Finland, Germany and the US. Nexstim is headquartered in Helsinki, Finland.

Nexstim Plc Key Recent Developments

Aug 04,2021: Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting
May 11,2021: Nexstim resolutions of the Annual General Meeting of Shareholders
Apr 20,2021: Correction to the Invitation to the Annual General Meeting of Nexstim
Apr 07,2021: Nexstim Plc: Final results of the successful rights issue
Mar 31,2021: Nexstim reschedules its Annual General Meeting to 11 May 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Nexstim Plc - Key Facts
Nexstim Plc - Key Employees
Nexstim Plc - Key Employee Biographies
Nexstim Plc - Major Products and Services
Nexstim Plc - History
Nexstim Plc - Company Statement
Nexstim Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Nexstim Plc - Business Description
Business Segment: NBS Other sales
Performance
Business Segment: NBS Systems
Overview
Performance
Key Stats
Business Segment: NBT Other sales
Performance
Business Segment: NBT Systems
Overview
Performance
Geographical Segment: Finland
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other
Performance
Geographical Segment: Rest of Europe
Performance
Nexstim Plc - Corporate Strategy
Nexstim Plc - SWOT Analysis
SWOT Analysis - Overview
Nexstim Plc - Strengths
Nexstim Plc - Weaknesses
Nexstim Plc - Opportunities
Nexstim Plc - Threats
Nexstim Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Nexstim Plc, Medical Equipment, Deals By Year, 2015 to YTD 2021
Nexstim Plc, Medical Equipment, Deals By Type, 2015 to YTD 2021
Nexstim Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 04, 2021: Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting
May 11, 2021: Nexstim resolutions of the Annual General Meeting of Shareholders
Apr 20, 2021: Correction to the Invitation to the Annual General Meeting of Nexstim
Mar 31, 2021: Nexstim reschedules its Annual General Meeting to 11 May 2021
Mar 01, 2021: Nexstim Resolutions of the Extraordinary General Meeting
Feb 19, 2021: Notice of Nexstim Plc 2020 Full Year Results
Nov 18, 2020: Nexstim signs a purchase agreement worth EUR 0.9 million to develop and deliver two prototype systems for a research project
Aug 14, 2020: Nexstim half-yearly report 1 January – 30 June 2020
Aug 13, 2020: Nexstim updates its corporate strategy
Jun 16, 2020: Nexstim : Mikko Karvinen appointed as permanent CEO and Joonas Juokslahti as permanent CFO

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Nexstim Plc, Key Facts
Nexstim Plc, Key Employees
Nexstim Plc, Key Employee Biographies
Nexstim Plc, Major Products and Services
Nexstim Plc, History
Nexstim Plc, Subsidiaries
Nexstim Plc, Key Competitors
Nexstim Plc, Ratios based on current share price
Nexstim Plc, Annual Ratios
Nexstim Plc, Annual Ratios (Cont...1)
Nexstim Plc, Interim Ratios
Nexstim Plc, Medical Equipment, Deals By Year, 2015 to YTD 2021
Nexstim Plc, Medical Equipment, Deals By Type, 2015 to YTD 2021
Nexstim Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Nexstim Plc, Performance Chart (2016 - 2020)
Nexstim Plc, Ratio Charts
Nexstim Plc, Medical Equipment, Deals By Year, 2015 to YTD 2021
Nexstim Plc, Medical Equipment, Deals by Type, 2015 to YTD 2021